A doubling of the net profit in the first quarter for the gAnglo-Swedish pharmaceutical group AstraZeneca, manufacturer of the Covid-19 vaccine, for which sales reached $ 275 million, beyond expectations. But the company said there will be no profits from this front during the pandemic. the first time a drug manufacturer has released financial details on the distribution and sale of its vaccines.
Sales of the vaccine in Europe were 224 million dollars, those in emerging markets of 43 million and 8 million in the rest of the world. Total revenue, which includes partnership payments, increased 11% to $ 7.32 billion. We expect the impact of Covid to anticipate an acceleration of performance in the second half of 2021, said CEO Pascal Soriot.
The laboratory, which reveals the turnover of the vaccine for the first time, reported net income of $ 1.56 billion in the first three months of the year, compared with $ 780 million for the same period last year. Astrazeneca also benefited from increased sales of new treatments, particularly in oncology, one of its specialties.